Navigation Links
BioMarin to Present at the Credit Suisse Healthcare Conference
Date:11/4/2009

NOVATO, Calif., Nov. 4 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will present a company update at the Credit Suisse Healthcare Conference in Phoenix on Wednesday, November 11, 2009 at 12:00 p.m. MST.

Interested parties may access a live audio webcast of the conference call via the investor section of the BioMarin website, www.BMRN.com. A replay of the call will be archived on the site for one week following the call.

About BioMarin

BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises three approved products and multiple clinical and pre-clinical product candidates. Approved products include Naglazyme® (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme® (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; and Kuvan® (sapropterin dihydrochloride) Tablets, for phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany. Other product candidates include PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase), which is in Phase II clinical development for the treatment of PKU and GALNS (N-acetylgalactosamine 6-sulfatase), which is currently in Phase I/II clinical development for the treatment of MPS IVA. For additional information, please visit www.BMRN.com. Information on BioMarin's website is not incorporated by reference into this press release.

BioMarin®, Naglazyme® and Kuvan® are registered trademarks of Bi
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. BioMarin Partner AnGes MG, Inc. Submits BLA to Japanese Ministry of Health
2. BioMarin Announces FDA Approval for Kuvan
3. BioMarin Initiates Phase 1 Clinical Study of PEG-PAL in PKU
4. BioMarin Announces Positive Results From Phase 2A Clinical Study of 6R-BH4 in Sickle Cell Disease
5. BioMarin Initiates Phase 1/2 Clinical Trial for GALNS for Morquio A Syndrome
6. BioMarin Initiates Phase 2 Clinical Study of PEG-PAL in PKU
7. BioMarin Acquires Huxley Pharmaceuticals, Inc.
8. BioMarin to Present at the Oppenheimer Healthcare Conference
9. BioMarin Announces Third Quarter 2009 Financial Results
10. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
11. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... Mich. , Aug. 22, 2014  Dr. ... Who with the Diamond Lifetime Achievement Award in the ... as CEO of Cardiovascular Clinical Associates. Dr. ... in managing all major aspects of the business; overseeing ... well as primary coronary intervention. In addition, he is ...
(Date:8/22/2014)... Zacks Equity Research highlights Epizyme (Nasdaq: EPZM - Free ... PNRA - Free Report ) as the Bear of the ... (Nasdaq: FOLD - Free Report ), Sanofi (NYSE: SNY ... Report ). Here is a synopsis of all five ... The biotech bull market is far from over due ...
(Date:8/22/2014)... ITHACA, N.Y. , Aug. 22, 2014 /PRNewswire/ ... computed tomography (CT) imaging facility, is using the ... 4D and even 5D imaging to researchers and ... just launched, asks "What would YOU do if ... the possibility to researchers and explorers everywhere, from ...
Breaking Medicine Technology:Dr. Mark Rasak, MD is recognized by Continental Who's Who with the Diamond Lifetime Achievement Award 2Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 2Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 3Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 4Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 5Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 6Cornell's X-ray Imaging Lab Director Uses Kickstarter Campaign to "Democratize" Advanced 3D Imaging 2
... Eli Lilly and Company (NYSE: LLY ) will ... on Wednesday, April 25, 2012.  Lilly will also conduct a ... media to further detail the company,s financial performance. ... to 10:00 a.m. EDT.  Investors, media and the general public ...
... Inc. , a biopharmaceutical company focused on the discovery, ... is in the human nervous system, today announced that ... the treatment of cough has cleared the 30 day ... (FDA).  The Company plans to immediately characterize the pharmacokinetics ...
Cached Medicine Technology:Cerecor Announces Clearance of IND for FP01 2
(Date:8/22/2014)... Counseling may do little to help young people with ... 66 studies that included nearly 18,000 people 25 and ... drinking problems. Participants in 49 studies attended a single ... the studies attended group sessions or a mix of ... motivational interviewing was used in the studies. This technique ...
(Date:8/22/2014)... FRIDAY, Aug. 22, 2014 (HealthDay News) -- College can be ... number of things they can do to make the most ... "a time to adjust, explore, meet new people and learn ... director of student wellness and assessment at St. John,s University ... "Not all learning takes place in the classroom. College ...
(Date:8/22/2014)... 22, 2014 Women with severe disabilities and multiple ... than women with no disabilities or no chronic conditions, ... screened less often than women with moderate disabilities or ... Sara Guilcher, an affiliate scientist with the Li Ka ... Guilcher said women with disabilities often have other measures ...
(Date:8/22/2014)... August 22, 2014 Ticket Down ... in Kalamazoo, New Orleans, Albuquerque and Rapid City. For ... “Long Island Medium,” Theresa Caputo, allows just that. Caputo was ... is part of a close knit family who began to ... a spiritual healer, realized she had a chance to do ...
(Date:8/22/2014)... (PRWEB) August 22, 2014 “Dr. Luciana Show ... Lagana , aka Dr. Luciana, is finding it challenging to ... and while taking care of hundreds of students, so the ... for the show is completed, and she recently entered it ... projects including those of her husband, actor/screenwriter Gregory Graham ...
Breaking Medicine News(10 mins):Health News:Counseling Does Little to Deter Youth Drinking, Review Finds 2Health News:College Prep 101 2Health News:Women with severe, chronic health issues are screened for breast cancer less often 2Health News:Theresa Caputo Tickets in Kalamazoo at Wings Stadium, Saenger Theatre in New Orleans, Kiva Auditorium in Albuquerque and Rapid City at Don Barnett Arena Now Available 2Health News:Professor Luciana Lagana Dedicates to Her CSUN Students the “Dr. Luciana Show-Aging and Falling” AOF Festival Nomination (Screening at Krikorian Monrovia Cinema on 08/25) 2Health News:Professor Luciana Lagana Dedicates to Her CSUN Students the “Dr. Luciana Show-Aging and Falling” AOF Festival Nomination (Screening at Krikorian Monrovia Cinema on 08/25) 3Health News:Professor Luciana Lagana Dedicates to Her CSUN Students the “Dr. Luciana Show-Aging and Falling” AOF Festival Nomination (Screening at Krikorian Monrovia Cinema on 08/25) 4
... among young inner-city children appears to be more unpredictable than ... a wise move as a hedge against dangerous flare-ups of ... study from the Johns Hopkins Childrens Center. Current asthma guidelines ... but six months may be too long for many patients, ...
... Johns Hopkins have evidence to explain why the supposedly natural ... factor for life-threatening heart failure. , In a ... Associations (AHA) annual Scientific Sessions in Orlando, Fla., the Hopkins ... and pumping function to assess minute changes in the hearts ...
... erase racial disparities, study suggests , SUNDAY, Nov. 4 (HealthDay ... patients vary widely by race and gender, a new U.S. ... South Carolina, Mt. Pleasant, noted that effective control of hypertension ... about actual rates of treatment and control. , The researchers ...
... from the Framingham Heart Study,link PAT signal with several cardio-vascular ... ... 4 Itamar Medical announced,confirmation of PAT technology by several ... Itamar Medical will now,promote clinical use in the medical community ...
... Carolina to increase the rate of coronary reperfusion (restoring ... significantly improved the quality of care these patients received, ... online to coincide with its release at the American ... in the November 28 print issue of JAMA. ...
... Combination Therapy Due to Flushing, ORLANDO, ... today,showed that Abbott,s SIMCOR(R), an investigational, fixed-dose ... met its primary endpoint of lowering plaque-promoting ... improvements,on other key lipids, LDL "bad" cholesterol, ...
Cached Medicine News:Health News:Urban kids with asthma need more frequent check-ups, Hopkins study suggests 2Health News:Aging heart changes shape, shrinks and loses pumping function too 2Health News:Aging heart changes shape, shrinks and loses pumping function too 3Health News:Poorer Blood Pressure Control in Blacks With Heart Failure 2Health News:New Research Released at AHA Confirms Itamar's PAT Technology to Diagnose Early Cardiovascular Disease 2Health News:Statewide program helps improve quality of care for heart attack 2Health News:Abbott's Investigational SIMCOR(R) Offers Comparable LDL Lowering to Simvastatin and Significantly Raises HDL and Lowers Triglycerides in Phase III Study 2Health News:Abbott's Investigational SIMCOR(R) Offers Comparable LDL Lowering to Simvastatin and Significantly Raises HDL and Lowers Triglycerides in Phase III Study 3Health News:Abbott's Investigational SIMCOR(R) Offers Comparable LDL Lowering to Simvastatin and Significantly Raises HDL and Lowers Triglycerides in Phase III Study 4Health News:Abbott's Investigational SIMCOR(R) Offers Comparable LDL Lowering to Simvastatin and Significantly Raises HDL and Lowers Triglycerides in Phase III Study 5
The DFS MiniFixator is a lightweight, external device for the treatment of small bone fractures and osteotomies....
The Elbow Fixator has ontrolled movement about the axis of rotation of the elbow joint. It is minimally invasive and rapidly applied....
... tradition of the original Hoffmann® Fixator, ... surgeon with advanced technology and ease ... snap fit mechanism allows the easy ... or pins providing versatile intraoperative frame ...
... safe and effective nonionic contrast medium well ... Worldwide, more than 250 million doses ... for a wide variety of radiological procedures, ... wide range of iodine concentrations and packaging ...
Medicine Products: